Lupin reported Q4 FY25 revenue of Rs 55,622 million, up 13.6% YoY and down 1% QoQ. Ebitda at Rs 12,921 million, surged by 29.6% YoY but was down 5.4% QoQ. Ebitda margin at 22.8%, expanded by 271 bps YoY but was down 88 bps QoQ. Lupin reported profit after tax of Rs 7,725 million, showing a growth of 114.9% YoY but was down 9.7% QoQ.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Report
Lupin Ltd.’s revenue (Rs 56,671 million), Ebitda (Rs 12,921 million) and Net earnings (Rs 7,725 million) were in-line with our estimates. Key growth drivers were the US, EMEA, and Other Developed markets. EMEA sales rose 30% YoY, fueled by a strong demand for Luforbec and NaMuscla.
North America grew 19% YoY, led by Mirabegron, Spiriva and gPredForte exclusivity, partially offset by Albuterol pricing pressure. Gross margins improved to 69% (up ~500 bps YoY from 64% in FY20), driven by a favorable product mix, reduced in-licensed product reliance, and cost efficiencies ($50 million saved in FY25).
Ebitda margins expanded to 22.8% (up ~271 bps YoY), supported by gross margin gains, despite an elevated research and development spend (9.4% of sales). Lupin believes it can maintain gross margins at ~69% with continued focus on complex generics and cost optimization.
Lupin also discussed its limited competition launch pipeline (details / names undisclosed) in the US and highlighted incremental launches in FY27 beyond those already in our estimates.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
Stock Picks Today: Tata Motors, Lupin, Coforge, Mphasis, Welspun Living, HDFC Life On Brokerages' Radar
Sep 30, 2025
Lupin Shares Jump Over 3% As Investec Hikes Target Price, Upgrades To 'Buy'
Sep 12, 2025
Buy Lupin, Says Investec After Stock Rating Upgrade; Share Price Target Hiked — What's Driving Growth?
Sep 12, 2025
Swiggy, Eternal See Higher Users Across Food Delivery, Quick Commerce; CLSA Hikes Target Price
Aug 21, 2025
POPULAR
